CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2018—Binding Site’s Immunologicals Group has introduced highly purified Borrelia and chikungunya glycoprotein antigens for use in IVD manufacturing and research applica-tions and as a component within solid phase ELISA-based immunoassay test procedures.
The antigens include Borrelia afzelii–Pko DbpA; Borrelia afzelii–Pko OspC; chikungunya glycoprotein–E2; chikungunya glycoprotein–E1; and chikungunya glycopro-tein–E1-A226V. They are derived and sourced from infected cells, via culture, which are then treated by heat, detergent, chemical, or UV irradiation to inactivate the pathogenic components. The company also added two Mycoplasma pneumoniae antigens; a native and a recombinant version of the antigen are available. The antigens exhibit high purity levels, demonstrate exceptional lot-to-lot consistencies, and feature a shelf-life stability claim of 10 years from the manufacturing date.
The company also announced the availability of a monoclonal IgG4 Clone-HP6025 antibody.